0582287 - FZÚ 2024 RIV US eng J - Článek v odborném periodiku
Štěpánková, K. - Chudičková, M. - Šimková, Z. - Martinez-Varea, N. - Kubinová, Šárka - Machová-Urdzíková, L. - Jendelová, P. - Kwok, J. C. F.
Low oral dose of 4-methylumbelliferone reduces glial scar but is insufficient to induce functional recovery after spinal cord injury.
Scientific Reports. Roč. 13, č. 1 (2023), č. článku 19183. ISSN 2045-2322. E-ISSN 2045-2322
Institucionální podpora: RVO:68378271
Klíčová slova: low oral dose * 4-methylumbelliferone * reduces glial scar * induce functional recovery * after spinal cord injury
Obor OECD: Pharmacology and pharmacy
Impakt faktor: 3.8, rok: 2023
Způsob publikování: Open access
DOI: https://doi.org/10.1038/s41598-023-46539-5

Spinal cord injury (SCI) induces the upregulation of chondroitin sulfate proteoglycans (CSPGs) at the glial scar and inhibits neuroregeneration. Under normal physiological condition, CSPGs interact with hyaluronan (HA) and other extracellular matrix on the neuronal surface forming a macromolecular structure called perineuronal nets (PNNs) which regulate neuroplasticity. 4-methylumbelliferone (4-MU) is a known inhibitor for HA synthesis but has not been tested in SCI. We first tested the effect of 4-MU in HA reduction in uninjured rats. After 8 weeks of 4-MU administration at a dose of 1.2 g/kg/day, we have not only observed a reduction of HA in the uninjured spinal cords but also a down-regulation of CS glycosaminoglycans (CS-GAGs).

Trvalý link: https://hdl.handle.net/11104/0350462